journal article·2021-12Open access

Hemagglutinin Nanoparticulate Vaccine with Controlled Photochemical Immunomodulation for Pathogenic Influenza‐Specific Immunity

Hayoon Jeong, Chung‐Sung Lee, Jangsu Lee, Jonghwan Lee, Hee Sook Hwang, Min Lee, Kun Na

Advanced Science· Volume 8· Issue 23

Abstract

Abstract Recently, viral infectious diseases, including COVID‐19 and Influenza, are the subjects of major concerns worldwide. One strategy for addressing these concerns focuses on nasal vaccines, which have great potential for achieving successful immunization via safe, easy, and affordable approaches. However, conventional nasal vaccines have major limitations resulting from fast removal when pass through nasal mucosa and mucociliary clearance hindering their effectiveness. Herein a nanoparticulate vaccine (NanoVac) exhibiting photochemical immunomodulation and constituting a new self‐assembled immunization system of a photoactivatable polymeric adjuvant with influenza virus hemagglutinin for efficient nasal delivery and antigen‐specific immunity against pathogenic influenza viruses is described. NanoVac increases the residence period of antigens and further enhances by spatiotemporal photochemical modulation in the nasal cavity. As a consequence, photochemical immunomodulation of NanoVacs successfully induces humoral and cellular immune responses followed by stimulation of mature dendritic cells, plasma cells, memory B cells, and CD4+ and CD8+ T cells, resulting in secretion of antigen‐specific immunoglobulins, cytokines, and CD8+ T cells. Notably, challenge with influenza virus after nasal immunization with NanoVacs demonstrates robust prevention of viral infection. Thus, this newly designed vaccine system can serve as a promising strategy for developing vaccines that are active against current hazardous pathogen outbreaks and pandemics.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Immunotherapy and Immune Responses · Influenza Virus Research Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biomedical‐Chemical Engineering The Catholic University of Korea Bucheon‐si Gyeonggi‐do 14662 Republic of Korea

Department of Biotechnology The Catholic University of Korea Bucheon‐si Gyeonggi‐do 14662 Republic of Korea

Division of Advanced Prosthodontics University of California Los Angeles Los Angeles CA 90095 USA

Department of Pharmaceutical Engineering and Biotechnology Sun Moon University Asan‐si Chungcheongnam‐do 31460 Republic of Korea

Department of Pharmaceutical Engineering Dankook University Cheonan‐si Chungcheongnam‐do 31116 Republic of Korea

Department of Bioengineering University of California Los Angeles Los Angeles CA 90095 USA

Funding

National Research Foundation of Korea

References (86)

Show source-provided references
1. 10.1038/s41565-020-0739-910.1038/s41565-020-0739-9 ↗
2. 10.1038/nm121310.1038/nm1213 ↗
3. 10.1021/acsnano.9b0032610.1021/acsnano.9b00326 ↗
4. 10.1038/nri177710.1038/nri1777 ↗
5. 10.1016/S0264-410X(02)00435-810.1016/S0264-410X(02)00435-8 ↗
6. 10.1016/j.biotechadv.2014.12.00410.1016/j.biotechadv.2014.12.004 ↗
7. 10.3109/0882013100368036910.3109/08820131003680369 ↗
8. 10.1038/nri143910.1038/nri1439 ↗
9. 10.1038/nri325110.1038/nri3251 ↗
10. 10.1080/21645515.2016.123966810.1080/21645515.2016.1239668 ↗
11. 10.1016/j.ijpharm.2019.11881310.1016/j.ijpharm.2019.118813 ↗
12. 10.1080/14760584.2017.139570210.1080/14760584.2017.1395702 ↗
13. 10.1016/j.jconrel.2016.02.01410.1016/j.jconrel.2016.02.014 ↗
14. 10.1111/cei.1328510.1111/cei.13285 ↗
15. 10.1007/s13238-015-0164-210.1007/s13238-015-0164-2 ↗
16. 10.3390/molecules1409375410.3390/molecules14093754 ↗
17. 10.1002/jps.260076070910.1002/jps.2600760709 ↗
18. 10.3389/fimmu.2019.0160510.3389/fimmu.2019.01605 ↗
19. 10.1016/j.addr.2009.11.01210.1016/j.addr.2009.11.012 ↗
20. 10.3109/1061186X.2010.52379010.3109/1061186X.2010.523790 ↗
21. 10.1021/acsnano.0c0610910.1021/acsnano.0c06109 ↗
22. 10.1016/j.eurpolymj.2019.03.00910.1016/j.eurpolymj.2019.03.009 ↗
23. 10.1016/j.jconrel.2015.10.01210.1016/j.jconrel.2015.10.012 ↗
24. 10.1038/nmat278410.1038/nmat2784 ↗
25. 10.2217/nnm.14.20010.2217/nnm.14.200 ↗
26. 10.3390/vaccines304080310.3390/vaccines3040803 ↗
27. 10.1021/acs.bioconjchem.7b0073810.1021/acs.bioconjchem.7b00738 ↗
28. 10.3389/fimmu.2013.0011410.3389/fimmu.2013.00114 ↗
29. 10.1016/j.immuni.2007.11.00310.1016/j.immuni.2007.11.003 ↗
30. 10.1016/j.ijpharm.2008.04.03610.1016/j.ijpharm.2008.04.036 ↗
31. 10.1038/nm.340910.1038/nm.3409 ↗
32. 10.3390/vaccines302032010.3390/vaccines3020320 ↗
33. 10.1038/nri251010.1038/nri2510 ↗
34. 10.1016/j.biomaterials.2020.12043110.1016/j.biomaterials.2020.120431 ↗
35. 10.1002/ange.20130288110.1002/ange.201302881 ↗
36. 10.1039/C4CC00746H10.1039/C4CC00746H ↗
37. 10.1016/j.nantod.2020.10089810.1016/j.nantod.2020.100898 ↗
38. 10.1021/nl803487r10.1021/nl803487r ↗
39. 10.1002/advs.20180000410.1002/advs.201800004 ↗
40. 10.1002/advs.20190010110.1002/advs.201900101 ↗
41. 10.1016/j.biopha.2016.07.05810.1016/j.biopha.2016.07.058 ↗
42. 10.1039/C5CC09239F10.1039/C5CC09239F ↗
43. 10.1016/j.biomaterials.2015.02.06010.1016/j.biomaterials.2015.02.060 ↗
44. 10.1111/php.1325310.1111/php.13253 ↗
45. 10.1016/j.biopha.2018.07.04910.1016/j.biopha.2018.07.049 ↗
46. 10.5411/wji.v4.i1.110.5411/wji.v4.i1.1 ↗
47. 10.1038/nrc189410.1038/nrc1894 ↗
48. 10.1586/eci.10.8110.1586/eci.10.81 ↗
49. 10.1016/0168-3659(90)90139-K10.1016/0168-3659(90)90139-K ↗
50. 10.1002/ange.20025065310.1002/ange.200250653 ↗
51. 10.1021/la010795310.1021/la0107953 ↗
52. 10.1016/j.biomaterials.2011.07.02310.1016/j.biomaterials.2011.07.023 ↗
53. 10.1038/s41598-020-61432-110.1038/s41598-020-61432-1 ↗
54. 10.1016/j.foodhyd.2013.10.02710.1016/j.foodhyd.2013.10.027 ↗
55. 10.1016/S0169-409X(97)00059-810.1016/S0169-409X(97)00059-8 ↗
56. 10.1016/0378-5173(96)04441-910.1016/0378-5173(96)04441-9 ↗
57. 10.1002/adfm.20180184010.1002/adfm.201801840 ↗
58. 10.1021/acsnano.5b0770610.1021/acsnano.5b07706 ↗
59. 10.1038/s41577-018-0046-y10.1038/s41577-018-0046-y ↗
60. 10.18632/oncotarget.1004710.18632/oncotarget.10047 ↗
61. 10.2174/138161282366617031612373610.2174/1381612823666170316123736 ↗
62. 10.1016/j.coi.2018.04.02610.1016/j.coi.2018.04.026 ↗
63. 10.1038/s41577-018-0088-110.1038/s41577-018-0088-1 ↗
64. 10.1016/S0952-7915(97)80153-710.1016/S0952-7915(97)80153-7 ↗
65. 10.3892/etm.2016.298910.3892/etm.2016.2989 ↗
66. 10.1038/nri227510.1038/nri2275 ↗
67. 10.1038/nri125610.1038/nri1256 ↗
68. 10.1038/s41577-019-0194-810.1038/s41577-019-0194-8 ↗
69. 10.1038/nri265410.1038/nri2654 ↗
70. 10.1016/S1081-1206(10)62426-X10.1016/S1081-1206(10)62426-X ↗
71. 10.3389/fimmu.2018.0067810.3389/fimmu.2018.00678 ↗
72. 10.4049/jimmunol.170.1.47710.4049/jimmunol.170.1.477 ↗
73. 10.1146/annurev.immunol.21.120601.14111410.1146/annurev.immunol.21.120601.141114 ↗
74. 10.1186/2162-3619-1-3610.1186/2162-3619-1-36 ↗
75. 10.1038/nri272910.1038/nri2729 ↗
76. 10.1038/nri157210.1038/nri1572 ↗
77. 10.1038/nri380210.1038/nri3802 ↗
78. 10.1038/8053810.1038/80538 ↗
79. 10.1016/j.vaccine.2017.11.06510.1016/j.vaccine.2017.11.065 ↗
80. 10.1038/s41467-017-00928-310.1038/s41467-017-00928-3 ↗
81. 10.1016/j.biomaterials.2013.08.03710.1016/j.biomaterials.2013.08.037 ↗
82. 10.1016/j.jconrel.2013.07.01210.1016/j.jconrel.2013.07.012 ↗
83. 10.1364/BOE.2.00123310.1364/BOE.2.001233 ↗
84. 10.1038/nprot.2014.18010.1038/nprot.2014.180 ↗
85. 10.1099/vir.0.036715-010.1099/vir.0.036715-0 ↗
86. 10.1093/oxfordjournals.aje.a11840810.1093/oxfordjournals.aje.a118408 ↗